stride semaglutide ACC25 trial #Semaglutide en Enf vascular periférica Sintomática y DBT2 🔴Estudio multicentrico 792👥 🔴Sema mejoró el punto final primario en ⬆️caminata 6 min a las 52 sem y los PF secundarios @americancollegeofcardiology Expanding cardiovascular indications for semaglutide:

Semaglutide works solely as a GLP-1 receptor agonist, which essentially tells your brain that you're full

Heres the tricky part: losing weight might mean losing more than just fat

Alternative GLP-1 medications If tirzepatide specifically is not accessible, other GLP-1 receptor agonists provide meaningful weight loss and metabolic benefits, though the dual-agonist mechanism of tirzepatide gives it an edge in clinical data

The mental hurdle is bigger than the physical one

Putting the pieces together before you fill The reason two people quote wildly different numbers for the same medication is that they are standing at different points in this stack